Manca Claudia, Hill Carol, Hujer Andrea M, Patel Robin, Evans Scott R, Bonomo Robert A, Kreiswirth Barry N
Public Health Research Institute Center, New Jersey Medical School-Rutgers University, Newark.
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S13-S17. doi: 10.1093/cid/ciw826.
The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators. The LC, in collaboration with the ARLG Leadership and Operations Center, developed procedures for review and approval of strain requests, guidance during the selection process, and for shipping strains from the distributing laboratories to the requesting investigators. ARLG strains and scientific and/or technical guidance have been provided to basic research laboratories and diagnostic companies for research and development, facilitating collaboration between diagnostic companies and the ARLG Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of multiple diagnostic devices from a single patient sampling event. In addition, the LC has completed several laboratory-based studies designed to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTERMIND approach using purified bacterial strains. In collaboration with the ARLG's Statistical and Data Management Center (SDMC), the LC has developed novel analytical strategies that integrate microbiologic and genetic data for improved and accurate identification of antimicrobial resistance. These novel approaches will aid in the design of future ARLG studies and help correlate pathogenic markers with clinical outcomes. The LC's accomplishments are the result of a successful collaboration with the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC. This interactive approach has been pivotal for the success of LC projects.
抗菌耐药性领导小组(ARLG)实验室中心(LC)通过提供科学指导并支持标准/专业实验室服务,引领基于实验室的研究评估、开发和实施。该实验室中心已建立了一个实体生物样本库和一个虚拟生物样本库。实体生物样本库包含位于一个集中实验室的、来自ARLG资助研究的细菌分离株,可供ARLG研究人员使用。基于网络的虚拟生物样本库菌株目录包括ARLG研究人员公布的特征明确的革兰氏阳性和革兰氏阴性菌株。该实验室中心与ARLG领导与运营中心合作,制定了菌株申请的审查和批准程序、选择过程中的指导以及将菌株从分发实验室运送给申请研究人员的程序。已向基础研究实验室和诊断公司提供ARLG菌株以及科学和/或技术指导,以用于研发,促进诊断公司与ARLG评估多种感染诊断的主协议(MASTERMIND)计划之间的合作,该计划旨在从单次患者采样事件中评估多种诊断设备。此外,该实验室中心已完成了多项基于实验室的研究,旨在通过使用纯化的细菌菌株开发、测试和应用MASTERMIND方法来帮助评估新的快速分子诊断方法。与ARLG的统计和数据管理中心(SDMC)合作,该实验室中心开发了新颖的分析策略,将微生物学和遗传学数据整合起来,以改进和准确识别抗菌耐药性。这些新颖的方法将有助于未来ARLG研究的设计,并有助于将致病标志物与临床结果相关联。该实验室中心的成就得益于与ARLG领导与运营中心、诊断与设备委员会以及SDMC的成功合作。这种互动方式对LC项目的成功至关重要。